Novel approaches for myelodysplastic syndromes: Beyond hypomethylating agents

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 104-109

  Loaiza Bonilla, Arturo ^a   Gore, Steven D ^a   Carraway, Hetty E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

DNA methyltransferase inhibitor; Erythropoietin; Farnesyl transferase inhibitors; Histone deacetylase inhibitors; Lenalidomide

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; ELTROMBOPAG; EZATIOSTAT; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE P1; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR15 ANTIGEN; LENALIDOMIDE; LONAFARNIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BLOOD TRANSFUSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; DRUG CHOICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BENZOIC ACIDS; ENZYME INHIBITORS; HUMANS; HYDRAZINES; METHYLTRANSFERASES; MYELODYSPLASTIC SYNDROMES; PYRAZOLES; QUALITY OF LIFE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 76749119416     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366bb8     Document Type: Review

References (48)

1. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely 'preleukemia'. Blood 2002; 100:791.
2. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111:4841.
3. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81:104.
4. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296-6303.
5. Apperly JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481-487.
6. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451:335-339.
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
8. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009 [Epub ahead of print].
9. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114:2764-2773.
10. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66:6361-6369.
11. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome: systematic review and meta analysis. Haematologica 2009 [Epub ahead of print].
12. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803.
13. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of decitabine 5-day dosing schedule for treatment of MDS low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-57.
14. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27:3842-3848.
15. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27:1850-1856.
16. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919.
17. Sorror M, SandmaierB, Storer B, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246-4254.
18. Lim ZY, Ingram W, Brand R, et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2009 [Epub ahead of print].
19. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699-705.
20. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156-163.
21. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100:1570-1574.
22. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106:841-851.
23. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505-2511.
24. Garg R, Faderl S, Garcia-Manero G, et al. Phase II study of rabbit antithy-mocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 2009; 23:1297-1302.
25. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia: new agents. Semin Hematol 2006; 43:96-106.
26. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145:318-332.
27. Grinblatt DL, Yu D, Hars V, et al. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer 2009; 115:84-93.
28. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111:574.
29. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26:3607.
30. Gotlib J, Lavori P, Quesada S, et al. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009; 84:3-5.
31. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114:2364-2365.
32. Kantarjian H, Giles F, Greenberg P, et al. Effect of romiplostim in patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacyti-dine. Blood (ASH annual Meeting Abstracts). 2008; 112: Abstract 224.
33. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009 [Epub ahead of print].
34. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96:1655-1669.
35. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyl transferase inhibitor tipifarnib in intermediate to high-risk myelodysplastic syndrome. Blood 2007; 109:4158-4163.
36. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukae mia: a phase II study. Ann Hematol 2008; 87:881-885.
37. List A, Dewald G, Bennett J, Giagounidis A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456-1465.
38. List AF, Wride K, Dewald GW, et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 2007; 31 (Suppl. 1):S38.
39. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009; 113:3947-3952.
40. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syn dromes with karyotypes other than deletion 5q. Blood 2008; 111:86-93.
41. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26:5943-5949.
42. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5:e35.
43. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003; 77:342-350.
44. Adler V, Yin Z, FuchsSY, et al. Regulation of JNKsignaling by GSTp. EMBO J 1999; 18:1321-1334.
45. Meng F, Broxmeyer HE, Toavs D, et al. TLK199: a novel, small molecule myelostimulant. Proceedings of the Annual Meeting of the American Association for Cancer Research; March 24, 2001; New Orleans, LA. Abstract 1144; p. 214.
46. TM), a novel glutathione analog inhibitor of GST P1-1, causes proliferation and maturation of bone marrow precursor cells and correlates with clinical improvement in myelodysplastic syndrome (MDS) patients in a phase 2a study. Blood. December 5, 2004; San Diego, CA. Abstract 2372; p. 652a.
47. Raza A, Galili N, Callander N, et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009; 2:20.
48. Raza A, Galili N, Smith S, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009; 113:6533-6540.